UPDATE: Cantor Fitzgerald Starts Longboard Pharmaceuticals Inc (LBPH) at Overweight; Sees Near Double
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Forward Air (FWRD) Appoints Shawn Stewart as CEO
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Guggenheim Starts Longboard Pharmaceuticals Inc (LBPH) at Buy
April 6, 2021 6:18 AM EDTGuggenheim analyst Yantin Suneja initiates coverage on Longboard Pharmaceuticals Inc (NASDAQ: LBPH) with a Buy rating and a price target of $27.00.
For an analyst ratings summary and ratings history on Longboard Pharmaceuticals Inc... More
UPDATE: Citi Starts Longboard Pharmaceuticals Inc (LBPH) at Buy
April 6, 2021 3:04 AM EDT(Updated - April 6, 2021 5:09 AM EDT)
Citi analyst Neena Bitritto-Garg initiates coverage on Longboard Pharmaceuticals Inc (NASDAQ: LBPH) with a Buy rating and a price target of $37.00.
The analyst comments "Longboard, the neuroscience spinoff of Arena Pharmaceuticals (ARNA), is developing potential best-in-class... More
